Award Timing Disclosure |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Statement [Table] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Award Timing MNPI Disclosure [Text Block] |
The information below sets forth the compensation for the years ended December 31, 2025, 2024, and 2023 for the President of the Company.
Employee Benefits; Employment Agreement
Mr. Gold was entitled to participate in the Company’s health and life insurance program until that benefit was terminated in February 2024. On July 10, 2024, Mr. Gold resigned from his position as President and Chairman of the Board of the Company, effective immediately.
Dr. Jeereddi was appointed President and Chairman of the Board in July 2024. Dr. Jeereddi received no cash compensation in 2024 and $50,000 in 2025. The remainder of compensation awarded Dr. Jeereddi was in the form of shares of common stock.
Director Compensation
In order to conserve cash during the development of our business, our directors, who are not officers or employees, received no cash compensation in 2024. Mr. St. Lawrence was appointed lead director in August 2025 and was compensated $2,000 per month. No other non-officer directors received cash compensation in 2025. The Board issued shares of stock to directors as compensation for 2025 and 2024 as follows: In addition, Messrs. St. Lawrence, Leimkuhler and Gold received an option to purchase 25,000 shares of common stock and Dr. Policherla received an option to purchase 10,500 shares. Each grant had an exercise price of $0.95 per share and vests fully on the first anniversary of the grant. Dr. Jeereddi received an option to purchase 125,000 shares with an exercise price of $0.95 per share which vest 33 1/3% on the first anniversary and monthly at a rate of 2.77% from month thirteen through month 36.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Award Timing MNPI Considered [Flag] | false | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||